ReviewCancer metastasis reviews2016
Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management.
Review in Cancer metastasis reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Survival and functional outcomes following surgical repair of pathological fractures in dogs: A meta-analysis.Open veterinary journal · 2025Pooled it
- Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study.Nutrients · 2021Trial
- The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II.Oncotarget · 2017Trial
- A novel circulating osteoimmunological signature for diagnosis: integrating CXCL2, FYN, galectin-3, and STING in postmenopausal osteoporosis.Frontiers in physiology · 2026Article
- Mechanistic Insight into the Antioxidant and Antimicrobial Activities of Palm Oil-Derived Biomaterials: Implications for Dental and Therapeutic Applications.International journal of molecular sciences · 2025Review
- Exploring the impact of galectins on liver cancer: From immunopathogenesis to potential targets.World journal of gastroenterology · 2025Review
- The osteosarcoma immune microenvironment in progression: PLEK as a prognostic biomarker and therapeutic target.Frontiers in immunology · 2025Article
- Myoblast-Derived Galectin 3 Impairs the Early Phases of Osteogenesis Affecting Notch and Akt Activity.Biomolecules · 2024Article
- Glycobiology in osteoclast differentiation and function.Bone research · 2023Review
- Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma.Molecular therapy oncolytics · 2022Article
- Bone Regeneration and Oxidative Stress: An Updated Overview.Antioxidants (Basel, Switzerland) · 2022Review
- Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review.Cancers · 2021Review
- Galectin-3: an immune checkpoint target for musculoskeletal tumor patients.Cancer metastasis reviews · 2021Review
- IgE Antibodies against Cancer: Efficacy and Safety.Antibodies (Basel, Switzerland) · 2020Review
- Autocrine motility factor and its receptor expression in musculoskeletal tumors.Journal of bone oncology · 2020Review
- Amplification of autocrine motility factor and its receptor in multiple myeloma and other musculoskeletal tumors.Journal of bone oncology · 2020Article
- Galectin-3 and cancer stemness.Glycobiology · 2018Review
- Association of Serum Galectin-3 with the Acute Exacerbation of Chronic Obstructive Pulmonary Disease.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Review
- Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
The skeleton is frequently a secondary growth site of disseminated cancers, often leading to painful and devastating clinical outcomes. Metastatic cancer distorts bone marrow homeostasis through tumor-derived factors, which shapes different bone tumor microenvironments depending on the tumor cells' origin. Here, we propose a novel insight on tumor-secreted Galectin-3 (Gal-3) that controls the induction of an inflammatory cascade, differentiation of osteoblasts, osteoclasts, and bone marrow cells, resulting in bone destruction and therapeutic failure. In the approaching era of personalized medicine, the current treatment modalities targeting bone metastatic environments are provided to the patient with limited consideration of the cancer cells' origin. Our new outlook suggests delivering individual tumor microenvironment treatments based on the expression level/activity/functionality of tumor-derived factors, rather than utilizing a commonly shared therapeutic umbrella. The notion of "Gal-3-associated bone remodeling" could be the first step toward a specific personalized therapy for each cancer type generating a different bone niche in patients afflicted with non-curable bone metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.